# MRNA catalysts: Moderna, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mrna/catalysts

> Moderna, Inc. (MRNA) has 12 upcoming catalysts. The next is the MRNA-1018-H5 topline data readout, Jan to Apr 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Moderna, Inc. |
| Ticker | MRNA (Nasdaq) |
| SEC CIK | 1682852 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/mrna |

## Cash runway

Cash $7.98B as of 2026-09-30; quarterly burn $1.56B; about 15.3 months of runway at that rate (XBRL company facts, accession 0001682852-26-000197).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [KEYTRUDA® (pembrolizumab) trial start](https://sec-api.dev/pdufa/pembrolizumab) | MRNA |  | completed | "Following results of the Phase 1b study, we began enrollment of the Phase 2 portion of the study in June 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000022/mrna-20241231.htm)) |
| February 14, 2025 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000006/exhibit9912024q4pressrelea.htm)) |
| May 1, 2025 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm)) |
| May 2025 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "We have three commercial products—Spikevax®, our original COVID vaccine, mRESVIA®, our vaccine against respiratory syncytial virus (RSV), and mNEXSPIKE®, our next-generation COVID vaccine. mNEXSPIKE, our newest commercial product, was approved by the U.S. Food and Drug Administration (FDA) in May 2025 for individuals aged 65 years and older, as well as individuals aged 12 through 64 years with at least one underlying risk factor." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000044/mrna-20250630.htm)) |
| May 31, 2025 | [Moderna, Inc. PDUFA date](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | scheduled | "The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm)) |
| June 12, 2025 | [Moderna, Inc. PDUFA date](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | scheduled | "The FDA has assigned a PDUFA goal date of June 12, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000031/exhibit9912025q1pressrelea.htm)) |
| June 27, 2025 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06097299 (A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097299)) |
| June 30, 2025 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of June 30, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for RSV disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000044/mrna-20250630.htm)) |
| July 28, 2025 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT05127434 (A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127434)) |
| August 1, 2025 | [Moderna, Inc. FDA approval](https://sec-api.dev/companies/mrna/catalysts) | MRNA | lower respiratory tract disease | completed, approved | "Additionally, Moderna recently announced that the FDA has approved mRESVIA (mRNA-1345), expanding the previous indication, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/exhibit9912025q2pressrelea.htm)) |
| August 1, 2025 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000041/exhibit9912025q2pressrelea.htm)) |
| August 21, 2025 | [MRNA-1010 primary completion](https://sec-api.dev/pdufa/mrna-1010) | MRNA | Seasonal Influenza | completed | "NCT06602024 (A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-21 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602024)) |
| September 25, 2025 | [MRNA-1083 primary completion](https://sec-api.dev/pdufa/mrna-1083) | MRNA | Influenza; SARS-CoV-2 | completed | "NCT06508320 (A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-10-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06508320)) |
| September 30, 2025 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of September 30, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for RSV disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000075/mrna-20250930.htm)) |
| October 13, 2025 | [Mrna-1083 composition 1 dose a lot a primary completion](https://sec-api.dev/pdufa/mrna-1083-composition-1-dose-a-lot-a) | MRNA | Influenza; SARS-CoV-2 | completed | "NCT06864143 (A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06864143)) |
| October 20, 2025 | [Mrna-1273.214 primary completion](https://sec-api.dev/pdufa/mrna-1273-214) | MRNA | SARS-CoV-2 | completed | "NCT05436834 (A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-20 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05436834)) |
| November 4, 2025 | [MRNA-1647 primary completion](https://sec-api.dev/pdufa/mrna-1647) | MRNA | Cytomegalovirus Infection | withdrawn | "NCT05085366 (A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05085366)) |
| November 6, 2025 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285225000073/exhibit9912025q3pressrelea.htm)) |
| November 13, 2025 | [MRNA-1010 primary completion](https://sec-api.dev/pdufa/mrna-1010) | MRNA | Influenza | completed | "NCT05606965 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-13 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05606965)) |
| November 17, 2025 | [MRNA-1083 primary completion](https://sec-api.dev/pdufa/mrna-1083) | MRNA | COVID-19; Influenza | completed | "NCT06694389 (Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-17 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06694389)) |
| December 31, 2025 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of December 31, 2025, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease (LRTD) caused by RSV." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000033/mrna-20251231.htm)) |
| 2026 | [Intismeran topline data readout](https://sec-api.dev/pdufa/intismeran) | MRNA |  | scheduled | "The Phase 2 portion of the study includes cohorts in first-line metastatic melanoma, second-line+ metastatic melanoma and first-line metastatic NSCLC, and the Company expects a potential Phase 2 data readout in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/exhibit9912026q1pressrelea.htm)) |
| January 19, 2026 | [MRNA-1647 primary completion](https://sec-api.dev/pdufa/mrna-1647) | MRNA | Cytomegalovirus Infection | completed | "NCT04975893 (A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-19 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04975893)) |
| February 13, 2026 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000015/exhibit9912025q4pressrelea.htm)) |
| March 27, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT07117487 (A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07117487)) |
| March 31, 2026 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of March 31, 2026, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease caused by RSV." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htm)) |
| May 1, 2026 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000057/exhibit9912026q1pressrelea.htm)) |
| May 25, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06143046 (A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-05-25 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06143046)) |
| Jun 2026 | [Moderna, Inc. FDA advisory committee meeting](https://sec-api.dev/companies/mrna/catalysts) | MRNA | influenza disease in adults 50 | completed, positive | "In June 2026, the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously that the benefits of mRNA-1010 outweigh its risks for the prevention of influenza disease in adults 50 through 64 years of age and in adults 65 years of age and older." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm)) |
| June 30, 2026 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of June 30, 2026, we have four approved products, our COVID vaccines, Spikevax and mNEXSPIKE, our RSV vaccine, mRESVIA, and our flu plus COVID combination vaccine, mCOMBRIAX. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease caused by RSV." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000150/mrna-20260630.htm)) |
| July 24, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06067230 (A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-24 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06067230)) |
| July 31, 2026 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm)) |
| Aug 2026 | [Spikevax (spikevax) label expansion decision](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "•COVID vaccines: In August 2026, we announced that the FDA has approved the supplemental Biologics License Applications (sBLA) for the 2026-2027 formulas for Spikevax and mNEXSPIKE, containing the JN.1-lineage XFG subvariant of SARS-CoV-2 to help prevent COVID-19." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000197/mrna-20260930.htm)) |
| August 5, 2026 | [Intismeran PDUFA date](https://sec-api.dev/pdufa/intismeran) | MRNA |  | scheduled | "The U.S. FDA has assigned a PDUFA date for mRNA-1010 of August 5, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/exhibit9912026q2pressrelea.htm)) |
| August 18, 2026 | [MRNA-1345 topline data readout](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT06097299 (A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-08-18." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06097299?tab=results)) |
| September 16, 2026 | [MRNA-1010 topline data readout](https://sec-api.dev/pdufa/mrna-1010) | MRNA | Seasonal Influenza | completed | "NCT06602024 (A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-21 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06602024?tab=results)) |
| September 29, 2026 | [MRNA-1345 topline data readout](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT05127434 (A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE2, PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-09-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05127434?tab=results)) |
| October 8, 2026 | [MRNA-1083 topline data readout](https://sec-api.dev/pdufa/mrna-1083) | MRNA | Influenza; SARS-CoV-2 | completed | "NCT06508320 (A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-25 (ACTUAL); Lead Sponsor ModernaTX, Inc.; Results First Posted 2026-10-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06508320?tab=results)) |
| November 6, 2026 | [Moderna, Inc. earnings report](https://sec-api.dev/companies/mrna/catalysts) | MRNA |  | completed | "Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000194/exhibit9912026q3pressrelea.htm)) |
| Jan to Apr 2027 | [MRNA-1018-H5 topline data readout](https://sec-api.dev/pdufa/mrna-1018-h5) | MRNA | Influenza | scheduled | "NCT07496450 (A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07496450)) |
| January 2027 | [MRNA-1018-H5 primary completion](https://sec-api.dev/pdufa/mrna-1018-h5) | MRNA | Influenza | scheduled | "NCT07496450 (A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07496450)) |
| Feb to May 2027 | [MRNA-1403 topline data readout](https://sec-api.dev/pdufa/mrna-1403) | MRNA | Acute Gastroenteritis; Norovirus Acute Gastroenteritis | scheduled | "NCT06592794 (A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06592794)) |
| February 2027 | [MRNA-1403 primary completion](https://sec-api.dev/pdufa/mrna-1403) | MRNA | Acute Gastroenteritis; Norovirus Acute Gastroenteritis | scheduled | "NCT06592794 (A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-15 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06592794)) |
| Mar to Jun 2027 | [MRNA-1647 topline data readout](https://sec-api.dev/pdufa/mrna-1647) | MRNA | Cytomegalovirus Infection | scheduled | "NCT05683457 (A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-06 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05683457)) |
| March 2027 | [MRNA-1647 primary completion](https://sec-api.dev/pdufa/mrna-1647) | MRNA | Cytomegalovirus Infection | scheduled | "NCT05683457 (A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-06 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05683457)) |
| Nov 2028 to Feb 2029 | [MRNA-1982 topline data readout](https://sec-api.dev/pdufa/mrna-1982) | MRNA | Lyme Disease | scheduled | "NCT07561294 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-09 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07561294)) |
| November 2028 | [MRNA-1982 primary completion](https://sec-api.dev/pdufa/mrna-1982) | MRNA | Lyme Disease | scheduled | "NCT07561294 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-09 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07561294)) |
| Jan to Apr 2029 | [MRNA-1195 topline data readout](https://sec-api.dev/pdufa/mrna-1195) | MRNA | Multiple Sclerosis | scheduled | "NCT06735248 (A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-08 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06735248)) |
| January 2029 | [MRNA-1195 primary completion](https://sec-api.dev/pdufa/mrna-1195) | MRNA | Multiple Sclerosis | scheduled | "NCT06735248 (A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-08 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06735248)) |
| Aug to Nov 2029 | [MRNA-1283 topline data readout](https://sec-api.dev/pdufa/mrna-1283) | MRNA | SARS-CoV-2 | scheduled | "NCT07808697 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07808697)) |
| August 2029 | [MRNA-1283 primary completion](https://sec-api.dev/pdufa/mrna-1283) | MRNA | SARS-CoV-2 | scheduled | "NCT07808697 (A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-30 (ESTIMATED); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07808697)) |

## Drugs

- [Intismeran](https://sec-api.dev/pdufa/intismeran): 
- [MRNA-1010](https://sec-api.dev/pdufa/mrna-1010): Seasonal Influenza, Influenza
- [MRNA-1018-H5](https://sec-api.dev/pdufa/mrna-1018-h5): Influenza
- [MRNA-1083](https://sec-api.dev/pdufa/mrna-1083): Influenza, COVID-19
- [Mrna-1083 composition 1 dose a lot a](https://sec-api.dev/pdufa/mrna-1083-composition-1-dose-a-lot-a): Influenza
- [MRNA-1195](https://sec-api.dev/pdufa/mrna-1195): Multiple Sclerosis
- [Mrna-1273.214](https://sec-api.dev/pdufa/mrna-1273-214): SARS-CoV-2
- [MRNA-1283](https://sec-api.dev/pdufa/mrna-1283): SARS-CoV-2
- [MRNA-1345](https://sec-api.dev/pdufa/mrna-1345): Respiratory Syncytial Virus
- [MRNA-1403](https://sec-api.dev/pdufa/mrna-1403): Acute Gastroenteritis
- [MRNA-1647](https://sec-api.dev/pdufa/mrna-1647): Cytomegalovirus Infection
- [MRNA-1982](https://sec-api.dev/pdufa/mrna-1982): Lyme Disease
- [Spikevax (spikevax)](https://sec-api.dev/pdufa/spikevax): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mrna/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MRNA catalysts: Moderna, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mrna/catalysts

```bibtex
@misc{secapidev_companies_mrna_catalysts_20261116,
  title        = {MRNA catalysts: Moderna, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mrna/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mrna_catalysts_20261116","title":"MRNA catalysts: Moderna, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mrna/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
